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ABSTRACT 
Bhadra, Sankhadip M.S. Microbiology and Immunology Graduate Program, Wright State 
University, 2019. Enhanced expression of receptor tyrosine kinase Mer (MERTK) on 
SOCS3-treated polarized RAW 264.7 anti-inflammatory M2c macrophages. 
 
Macrophages are phagocytic cells located in tissues, organs and even circulated within our 
body as white blood cells. They are critical in detecting tissue damage and infection.  
Resident tissue macrophages initiate the signals for inflammation recruiting neutrophils 
and blood monocytes which mature into macrophages at sites of infection and in the 
resolution of inflammation. Based on the local cytokine milieu in tissue sites, macrophages 
may be polarized into pro-inflammatory M1 or anti-inflammatory M2 phenotypes. 
Receptor tyrosine kinase Mer (MERTK) helps in clearing dead neutrophils and other 
apoptotic cells from damaged tissue sites preventing chronic inflammation and 
autoimmune disorders. MERTK aids in the maintenance of tissue homeostasis and wound 
healing. Phosphatidylserine (PtdSer) present on the surface of apoptotic cells release “eat 
me” signals which are recognized by the two “bridging ligands” of MERTK receptor, Gas6 
and ProS. The binding of the ligands to PtdSer initiates intracellular signals leading to 
phagocytosis of the cell. MERTK receptor is expressed mostly on M2c macrophages. 
The current study explores the expression rate of the phagocytic receptor MERTK, on 
macrophages polarized with either IL-10 (M2c ells)  or IL-4 or IL-13 (M2a macrophages) 
following treatment with the suppressor of cytokine signaling SOCS3 in comparison with 
macrophage polarization with only  IL-10 or IL-4  or  IL-13 . 
The current study exhibits an enhancement in the expression of the phagocytic MERTK 
receptor on the surface of IL-10 polarized M2c macrophage when treated with SOCS3 in 
comparison to IL-10 polarized M2c macrophage, IL-4 polarized M2a macrophage and IL-
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13 treated M2a macrophage. IL-13 polarized M2a macrophage also shows an increase in 
the expression of MERTK receptor which is similar to a previous study where a similar 
receptor to MERTK termed “Axl receptor” is enhanced by IL-13 treatment on bone-
marrow derived macrophage. SOCS3 when treated with IL-13 polarized M2a macrophage 
acts as a negative regulator of MERTK receptor by decreasing the expression contrasting 
to the effect of SOCS3 on IL-10 which enhances the expression. 
 
Based on these observations, future research will involve co-culturing SOCS3 polarized 
M2 macrophages with apoptotic cells such as N2a neuroblastoma cells. 
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expression of MERTK receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv 
ACKNOWLEDGEMENTS 
 
Firstly, I would like to dedicate my work to Mom and Dad for their constant support, 
backing and trust on me and my field of interest. I wouldn’t have been able to love what I 
am doing without the freedom provided to me by them. 
I am privileged to work under my advisor and guide Dr. Nancy J. Bigley, who opened her 
laboratory and played a significant role in shaping this study. Her vast knowledge in the 
field of immunology and her passion for research has motivated me throughout the time 
spent in working under this project. A big thank you to my committee members Dr. Dawn 
P. Wooley and Dr. Marjorie M. Markopoulos for their suggestions and feedback on my 
report. 
The study would not be completed without my current and former lab colleagues, who have 
trained me in learning new techniques, helped me when I got stuck in between experiments 
and provided me with valuable inputs while writing my thesis. A big high-five to all my 
friends who constantly encouraged and pushed me during difficult times and whenever 
laziness stepped in between. 
I cannot end without thanking all my teachers from school and college who have always 
imparted knowledge, dealt patiently with all my doubts and queries and instilled confidence 
in me throughout. 
I am grateful to Wright State University for giving me the golden opportunity to study 
abroad and providing an environment where I enjoyed conducting my research. 
 
 
1 
INTRODUCTION 
 
Capan (2017) showed an increase in phagocytosis of N2a tumor cells by the M1 phenotype 
of murine RAW 264.7 macrophages following treatment of the macrophages with SOCS1 
peptide mimetic. There was no such enhancement in IL-10 polarized M2 macrophages. In 
contrast, SOCS3 treatment increased phagocytosis of the tumor cells by IL-10 polarized 
M2 macrophages of the tumor target cells in which the calreticulin (CRT) “eat-me” signal 
was blocked by anti-CRT.  CRT is an “eat me” signal present on the surface of apoptotic 
cells. Consequently, Madhkhali (2019) examined the effects of SOCS3 on two populations 
of M2a-polarized macrophages for phagocytosis of the N2a tumor cells treated with anti-
CRT. First, she noted insignificant increases in the phagocytic ability of SOCS1-treated 
M2a and M2c macrophages for the anti-CRT-treated tumor cell N2a cells, while SOCS3 
treatment of these same cells upregulated the phagocytic capacity of these macrophage 
phenotypes cells for N2a cells. 
 
This current study is an extension of the observations of Capan (2017) and Madhkhali 
(2019) and focused on the SOCS peptide mimetics effect on the expression of MERTK 
receptor on M2 macrophage phenotypes (Figure 4). IL-10 polarized M2c and IL-4/IL-13 
polarized M2a macrophage phenotypes were used.  Because Nishi et al. (2014) showed 
that the MERTK “eat-me” signal on macrophages was enhanced by phosphorylation upon 
contact with apoptotic cells, we wanted to determine whether SOCS3 peptide could also 
increase expression of MERTK by immunofluorescence. This seems likely because Zhang 
et al. (2016) showed that blocking MERTK expression on RAW 264.7 macrophages also 
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suppressed expression of SOCS3. Immunofluorescence led to comparison on the 
upregulation of MERTK receptor expression when treated with SOCS3 and SOCS1 along 
with the polarizing other cytokines IL-10, IL-4 and IL-13. 
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LITERATURE REVIEW 
 
1.1 Macrophage subtypes 
The fight of the immune system against bacterial and viral pathogens involve phagocytic 
cells which recognize, bind and engulf pathogens, leading to their clearance from the 
immune system. Innate immunity is the first line of defense against any pathogen-
associated infection which leads to inflammation initiating healing process in the body 
against tissue damage and injuries. 
It has been a century since the discovery of macrophages by Nobel Prize in Medicine 
winner Ilya Metchnikoff. Macrophages play a significant role in regulating the innate 
immune response (Saqib et al., 2018). They are able to differentiate between apoptotic, 
necrotic and viable cells without triggering inflammation and immune responses (Gordon 
et al., 2018). The apoptotic nature of the macrophages plays a major role in the 
development of organs, tissue remodeling, and post-injury cell replacement (Gordon et al., 
2018). The generation of specific tissue and microbial stimuli to phagocytose materials 
affects the heterogeneous nature of mononuclear phagocytes in tissues (Gordon et al., 
2018). They are a type of phagocytic cell which can be differentiated into proinflammatory 
macrophage (M1) and anti-inflammatory macrophage (M2) based on their reactions to 
different growth factors and cytokines (Xu et al., 2006).  
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1.2 Macrophage polarization 
Arginine metabolism led to the differentiation between M1 and M2 macrophages in T 
helper type 1 (Th1) (C57BL/6) and T helper type 2 (Th2) (Balb/c) strains of mice (Mills et 
al., 2000). Classical M1 activation is stimulated by IFN-g and TLR ligands whereas 
alternative M2 macrophages are activated by IL-10, IL-4 and IL-13 (Mantovani et al., 
2012). Different stimuli and transcriptional factors led to the induction of different subtypes 
of M2 macrophages namely M2a, M2b, M2c and M2d (Mantovani et al., 2004). M2a 
subtype is triggered by IL-4, IL-13 and infections caused by fungus and helminth. IL-10, 
IL-13, IL-4, dexamethasone and macrophage colony stimulating factor (M-CSF) 
stimulates M2 macrophages (Myers et al., 2019). IL-10, TGF-b and glucocorticoids 
triggers M2c whereas immune complexes and LPS generates M2b subtype. 
Pro-inflammatory cytokines are produced by M1 macrophages and they have 
characteristics involving microbicidal properties, pathogenic resistance, and Th1 
responses. M1 macrophages cause inflammation which is deleterious to health. 
M2 macrophages involves enhanced phagocytic activity, tumor production, tissue 
remodeling, and parasitic control. The M2 macrophages are polarized into anti-
inflammatory cytokines like interleukin-10 (IL-10), which assist M2 in engulfing and 
clearing the apoptotic cell (Xu et al., 2006). The interaction between apoptotic cells and 
phagocytes are based on three signals, “find me”, “eat me”, and “don’t eat me”. Previous 
analysis and reports suggested that phagocytosis displayed an anti-inflammatory response 
through upregulation of CD 163 and CD206 receptors (Gordon et al., 2018). The 
maintenance of immune system under normal physiological conditions is termed as 
“immune homeostasis” which can be disrupted if the M1-M2 balance in the body is not 
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regulated. Beside homeostasis, macrophages control tissue remodeling and metabolism. 
The damaged cells are termed as “apoptotic cells” which need to be cleared from the body 
to maintain immune homeostasis; the M2 macrophage plays a crucial role in engulfing 
these dead cells, preventing inflammation and formation of auto-immune diseases (Xu et 
al., 2006). 
Xu et al., 2006 hypothesized that an anti-inflammatory phagocytic subset is responsible for 
recognizing and clearing the apoptotic cell, preventing autoimmunity and maintaining 
immune homeostasis. The macrophage colony stimulating factor (M-CSF) driven M2 has 
anti-inflammatory property producing IL-10 and granulocyte-macrophage CSF (GM)-CSF 
driven M1 has pro-inflammatory properties producing IL-6 and TNF-a. The authors 
suggest that IL-10 producing M2 macrophages are involved in the apoptotic cell 
recognition and clearance process. 
The diverse and flexible nature of monocyte-macrophage lineage cells marks the authentic 
nature of these cells (Funes et al., 2018). 
 
1.3 Anti-inflammatory cytokines 
Parasitic infection and allergies trigger Type 2 immunity in tissues which leads to an initial 
response at mucosal barriers, which is then amplified and activated by effector cells 
followed by tissue repair mechanisms (Dyken et al., 2013). Type 2 immunity shifts from 
proinflammatory cytokine and nitric oxide production to anti-inflammatory molecules and 
tissue repair mechanisms through IL-4 and IL-13. 
IL-13, a T-cell derived cytokine (Th2 type), along with IL-4, controls and operates the 
immune response (Elsner et al., 2011). The morphology, phenotype, and functioning of 
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monocytes are controlled in a similar way by both IL-13 and IL-4 (Lomo et al., 1997). It 
also plays a primary role in some chronic inflammatory diseases like asthma and ulcerative 
colitis (Elsner et al., 2011). Beside the similarities between these two cytokines, there are 
some differences. IL-13 is inactive on T cells due to the absence of receptors on these cells. 
IL-4 is primarily generated by helper TH2 subset, whereas all three T helper subsets TH0, 
TH1, and TH2 release IL-13 (Lomo et al., 1997). Janus kinases JAK1 and JAK3 proteins 
are activated by IL-4 but IL-13 can only activate JAK1 (Lomo et al., 1997). 
Type II IL-4 receptor contains IL13Ra1, made up of dimers IL4Ra and IL13Ra1 chain to 
which both IL-4 and IL-13 binds (Elsner et al., 2011). IL-4 also binds to Type I receptor 
but IL-13 is solely dependent on IL13 Ra1 (Elsner et al., 2011). Hence, it has been proved 
that the binding sites of IL-13 and IL-4 shares a common signaling subunit. 
 
1.4 Phagocytosis by macrophages 
These Type II receptors phosphorylate and activates Janus tyrosine kinases (JAK) proteins 
which are bound to these receptors in unstimulated cells. Phosphorylated JAK proteins 
phosphorylates IL4Ra chain which binds, dimerizes, and activates STAT6 which 
translocate to the nucleus regulating specific transcription. 
The action of CD103+CD11b+ and CD11b+ macrophages on apoptotic intraepithelial cells 
enhances the expression of growth arrest specific protein 6 (Gas6) and MERTK genes 
(Gordon et al., 2018). The transcription factor Kruppel-like factor-2 (KLF2) regulates the 
expression of genes responsible for phagocytosis by macrophages (Gordon et al., 2018). 
CX3CR1+CD64+MERTK+CD11c+ resident macrophages are the major efferocytic cells in 
the T zone of lymph nodes. 
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The cells on the verge of death trigger signals inducing mitosis and mutual interaction with 
macrophages (Gordon et al., 2018). 
 
1.5 Receptor tyrosine kinase Mer (MERTK) 
The family of receptor tyrosine kinase (TAM) removes apoptotic cells through 
efferocytosis. These receptors polarize macrophages to an alternatively-active form of M2 
phenotype (Myers et al., 2019). The immunoregulatory functions of the tyrosine receptor 
kinase family (Tyro3, Axl and MERTK) in macrophages and dendritic cells assist in 
phagocytosis and clearance of apoptotic cells. The injured tissues could be repaired by 
macrophages through an apoptotic ligand detected by MERTK and Axl. 
Mer receptor tyrosine kinase (MERTK) receptor was originally derived from v-ryk 
oncogene of avian retroviruses and was placed under the Axl receptor family (Myers et al., 
2019). MERTK is also mentioned as MER, RP38, c-Eyk, c-mer and Tyro12 in several 
contexts (Myers et al., 2019). MERTK receptor plays a major role in efficiently removing 
dead neutrophils and maintaining homeostasis during IL-10 production to prevent the 
formation of chronic inflammation and autoimmunity (Zizzo et. al, 2018). The receptor 
performs dual role in binding the apoptotic cells to the surface of the macrophages and 
engulfing the cells (Figure 1). There are two specific ligands Gas6 and Protein S which 
activates the receptors of the TAM family (Tyro3, Axl and MERTK). Phosphatidylserine 
(PtdSer) located on the plasma membrane of the apoptotic cell acts as an “eat me” signal 
when the amino terminal Gla domain of Gas6 and Protein S binds to it (Dransfield et al., 
2015) (Figure 3). The “eat me” signal generated by the apoptotic cell is recognized and 
then internalized by macrophages (Dransfield et al., 2015). The autocrine production of 
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Gas6 ligand of MERTK receptor by M2c polarized cells stimulates the production of IL-
10. Studies on murine macrophages have observed a synergistic interaction of MERTK 
receptor with other receptors involved in phagocytosis like avb5 integrin, scavenger 
receptor A (SR-A) and C1q (Zizzo et. al, 2018). 
 
Figure 1: Structure of MERTK receptor. The receptor contains two immunoglobulin-
like repeats domain (IgL) and two fibronectin type III repeats domain (FNIII) exposed on 
the outer surface of the macrophage. The tyrosine kinase domain (TKD) is embedded in 
the cytoplasm. Adapted from Myers, K. V., Amend, S. R., & Pienta, K. J. (2019). Targeting 
Tyro3, Axl and MERTK (TAM receptors): implications for macrophages in the tumor 
microenvironment. Molecular cancer, 18(1), 94. 
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Figure 2: The ligands of the MERTK receptor Gas6 and Protein S contains a single 
domain of g-carboxyglutamic acid (Gla), four domains of epidermal growth factor repeats 
(EGF) and two domains of laminin G (LG) like domains. Adapted from Myers, K. V., 
Amend, S. R., & Pienta, K. J. (2019). Targeting Tyro3, Axl and MERTK (TAM receptors): 
implications for macrophages in the tumor microenvironment. Molecular cancer, 18(1), 
94. 
 
The “two bridging ligands” Gas6 and Pro S of MERTK receptor shares structural 
similarity. They comprise of an amino terminus γ-carboxyglutamic acid (Gla) domain 
followed by four epidermal growth factor (EGF) like domain repeats and two laminin G 
(LG) like domain at the carboxy terminus end (Myers et al., 2019) (Figure 2). 
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Figure 3: Phosphatidyl serine (PtdSer) on the surface of apoptotic cell acts as an “eat 
me” signal which binds to the “bridging ligands” of MERTK receptor Gas6 and 
Protein S. The “eat me” signal is transported from the outer environment to the cytoplasm 
of the macrophage by the cytoplasmic domain tyrosine kinase (TKD) which leads to 
phagocytosis. Adapted from Myers, K. V., Amend, S. R., & Pienta, K. J. (2019). Targeting 
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Tyro3, Axl and MERTK (TAM receptors): implications for macrophages in the tumor 
microenvironment. Molecular cancer, 18(1), 94. 
 
Phosphatidylserine (PtdSer) located in the lipid membrane of the apoptotic cell serves as 
an “eat me” signal to the macrophages through high affinity binding to the Gla domain of 
Gas6 and Pro S ligand (Myers et al., 2019). The LG domain is bound to the TAM receptors. 
The binding of the ligands to PtdSer is followed by receptor dimerization and the tyrosine 
kinase domain (TKD) is auto-phosphorylated (Myers et al., 2019). This triggers the 
intracellular signaling cascades of the macrophage initiating phagocytosis of apoptotic 
cells. 
 
1.6 Suppressor of cytokine signaling (SOCS) 
Polarization of M1 and M2 macrophages are controlled by a family of intracellular 
cytokine activated proteins termed SOCS. The SOCS family consists of eight proteins 
(SOCS1-SOCS7 and CIS). Resting macrophages has lower expression of these proteins 
and are enhanced upon activation (Wilson, 2014). The SOCS family of proteins are 
structurally organized into three domains which includes a variable amino terminal 
domain, a carboxy-terminal box motif, and Src homology 2 (SH2) domain (Wilson, 2014). 
SOCS proteins comprise a region of seventy amino acids termed as the SOCS box followed 
by a SH2 domain. SOCS1 and SOCS3 has an additional twelve amino acid extended SH2 
domain called the Kinase Inhibitory Region (KIR) (Qasimi et al., 2006). 
Cytokines, toll-like receptors (TLR), and immune complexes are common activators and 
inducers of both macrophages and SOCS protein. The interaction between phosphorylated 
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tyrosine residues with JAK proteins or cytokine receptors negatively regulates JAK/STAT 
signaling by SOCS proteins (Wilson, 2014). The kinase inhibitory region (KIR) present on 
SOCS1 and SOCS3 proteins leads to direct suppression of JAK tyrosine kinase activity 
(Wilson, 2014). 
 
1.7 SOCS1 and SOCS3 
The inhibition of IFN-g induced JAK2/STAT1 pathway and TLR/NF-kb signaling 
modulates M1 macrophage activation by SOCS1 (Wilson, 2014). Expression of SOCS1 is 
enhanced within a M2 polarizing habitat in vitro and in vivo whereas SOCS3 is upregulated 
in a M1 polarizing niche in vivo (Wilson, 2014). SOCS1 controls the iNOS/Arginase I 
expression ratio to counteract the immune responses during sudden changes within the 
microenvironment (Wilson, 2014).  
SOCS3 expression is upregulated in pro-inflammatory M1 macrophage surroundings in 
vivo. They regulate TLR4 signaling and activates M1 macrophages by inhibiting STAT3 
activation (Wilson, 2014). Treatment of macrophages with lipopolysaccharide (LPS) 
produces IL-10, IL-6, and TGF-b enhancing SOCS3 expression (White et al., 2011). 
 
1.8 Effect of SOCS3 on macrophages 
SOCS3 protein enhances the expression of receptor tyrosine kinase Mer (MERTK) which 
helps in increasing the phagocytic nature of M2 macrophages (Zhang et al., 2016). Reports 
suggest that lipoteichoic acid (LTA) induced activation of MERTK receptor through TLR2 
signaling in RAW 264.7 macrophages upregulated the expression of SOCS3 (Zhang et al., 
2016). 
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Figure 4: Layout of the current study. M0 macrophages were polarized into cytokine 
treated M1 (IFN-g) and M2 (IL-10, IL-4 and IL-13) macrophages. Addition of SOCS3 
leads to contrasting effects on the expression of MERTK receptors on IL-13 polarized M2a 
and IL-10 polarized M2c macrophages.  
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MATERIALS AND METHODS 
2.1 Cell lines 
RAW 264.7 macrophage transformed cell lines from Abelson leukemia viruses were used 
in this project obtained from American Type Culture Collection (ATCC). This particular 
cell line was obtained from an adult male BALB/c mouse. These adherent cells were grown 
overnight in HyClone Dulbecco’s Modified Eagle Medium (DMEM) (Fisher Scientific) 
supplemented with 10% HyClone Fetal Clone II Serum (Fisher Scientific) on 25 cm2 and 
75 cm2 sterile BioLite Cell Culture treated flasks (Fisher Scientific). The cultured flasks 
were incubated in a humid environment with 5% carbon dioxide (CO2) at 370C. The cells 
undergo multiple passages before they are ready for treatment and are split once they reach 
70% confluency by scraping the surface of the flask using cell scrapers (Fisher Scientific). 
 
2.2 Macrophage polarization treatment 
The M0 RAW 264.7 macrophage cells were grown in 75 cm2 cell culture flasks and 
incubated overnight to approximately 70% growth confluency. The cells adhere to the 
surface of the culture flasks and were removed via cell scraper (Fisher Scientific), 
transferred to a 15 mL centrifuge tube, and centrifuged at 1700 revolutions per minute 
(40C) for five minutes. The supernatant was removed using a vacuum tube and the pellets 
were re-suspended in 1 mL of 10% DMEM growth medium. The cells were counted using 
hemocytometer and were aliquoted in 25 cm2 culture flasks at a seeding density of 1.0 x 
106 cells per flask. These M0 macrophage cells were polarized into M2c macrophages by 
treating them separately with IL-10, IL-4, & IL-13 (BioLegend) at a concentration of 20 
ng/mL (Table 1). SOCS1-KIR (GenScript) and SOCS3-KIR (GenScript) peptide mimetics 
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were also used in the presence and absence of IL-4, IL-10, and IL-13 to measure the 
expression of MERTK receptor at a concentration of 35 µM (Table 1). The cells were 
incubated for 24 hours post-cytokine and SOCS1/3 treatment. 
Table 1: Cytokines and SOCS protein concentrations used for the current study. 
 
Treatment Concentration 
IL-10 20 ng/mL 
IL-13 20 ng/mL 
IL-4 20 ng/mL 
IFN-g 20 ng/mL 
SOCS1-KIR 35 µM 
SOCS3-KIR 35 µM 
 
 
2.3 Cell counting 
Untreated cells and treated cells with cytokines and SOCS1/3 were scraped from the culture 
flasks 24 hours post incubation, transferred to a 15 mL centrifuge tube and centrifuged at 
1700 revolutions per minute (40C) for five minutes. The supernatant was removed by using 
a vacuum tube and the pellets were re-suspended in 1 mL of 10% DMEM growth medium. 
The re-suspended cells were stained with trypan blue (Fisher Scientific) at a 1:2 ratio and 
added to a hemocytometer for cell counting and viability. The viable cells appeared 
translucent whereas dead cells were stained blue when observed under phase contrast 
microscope. 
The following equation was used for cell count and cell viability: 
Cell confluency = [(Number of cells in hemocytometer (5 boxes) / 5) x 250 x 2] / 1000 
Cell viability = [Viable cells (translucent)/Total number of cells (dead and alive)] x 100 
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2.4 Flow cytometry (Cell Surface Staining) 
Both treated (polarized) and non-treated (control) RAW 264.7 macrophage cells were 
scraped, centrifuged and checked for cell count and viability. Around two million cells 
were added to 1.5 mL centrifuge tubes and centrifuged at 11,000 revolutions per minute at 
40C for six minutes. The supernatants were removed, and pellets were treated with 1 mL 
of Cell Staining Buffer (BioLegend). The cells were centrifuged at 2100 revolutions per 
minute at 40C for six minutes. 
FITC anti-mouse MERTK (Mer) Antibody (BioLegend) and FITC Rat IgG2a, k Isotype 
Control Antibody (BioLegend) were diluted at a ratio of 1:100 with Cell Staining Buffer 
(BioLegend) (Table 2). These conjugated antibodies are light sensitive, so all further steps 
were performed in the dark. The pellets were treated with 100 µL of the diluted antibody 
and its isotype. The antibody treated cells were incubated in ice for fifteen minutes in the 
dark. The cells were centrifuged at 1100 revolutions per minute at 40C for six minutes. The 
supernatant was removed, and the cells were washed thrice with 1 mL of Cell Staining 
Buffer (CSB) (BioLegend). After every wash, the cells were centrifuged at 2100 
revolutions per minute at 40C for six minutes. The final pellets were resuspended in 500 
µL of Cell Staining Buffer (CSB) and incubated for five minutes at room temperature. The 
cells were filtered through Falcon tubes and transferred to a fresh 1.5 mL centrifuge tube. 
The samples were analyzed on Accuri C6 Flow Cytometer (BD Biosciences) and raw data 
was transformed into flow histogram in FCS Express 6 Flow Cytometry Software (De 
Novo Software). 
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Table 2: Primary antibody and isotype concentrations used for the current study. 
 
Antibody Concentration (Stock) Company 
FITC anti-mouse MERTK 
(Mer) 
0.5 mg/mL BioLegend 
FITC Rat IgG2a, k Isotype 
Control 
0.5 mg/mL BioLegend 
 
2.5 Immunofluorescence staining 
20,000 cells were seeded per well, in a 12 well chamber slide along with the required 
treatment of IL-10, IL-4, IL-13, and SOCS1/3 on the cells. The total volume per well of 
the chamber slide was filled with 200 µL with 10% DMEM growth medium. The chamber 
slides were incubated for 24 hours in a humid environment with 5% carbon dioxide (CO2) 
at 370C. The cells adhered to the base and the media was aspirated the following day and 
washed thrice with 200 µL of chilled 1X HyClone Phosphate Buffer Saline (PBS) (GE Life 
Sciences). The cells were fixed with 4% paraformaldehyde for 15 minutes at room 
temperature and washed thrice with 200 µL of chilled 1X PBS. Cell Staining Buffer (CSB) 
was used as a blocking agent and 200 µL was added to the cells for 30 minutes and then 
washed thrice with 200 µL of chilled 1X PBS. FITC anti-mouse MERTK (Mer) Antibody 
(BioLegend) were diluted at a ratio of 1:100 in PBS with 5% Fetal Bovine Serum (FBS). 
The diluted antibody was added to each well and incubated in dark for an hour at 40C.  
 
2.6 Cell mounting for viewing 
The antibody solution was removed and washed twice with cold 1X PBS. The PBS was 
aspirated completely, the silicone wells were removed, and the slide was left to dry. Several 
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drops of VECTASHIELD Antifade Mounting Medium (Vector Laboratories) was added 
along the center of the slide. The coverslip was placed on top of the VECTASHIELD and 
allowed to harden for twenty minutes. The edges of the coverslip were sealed using nail 
polish and the slides were visualized using ACCU-SCOPE EXC-350 microscope with 
scope LED fluorescence illuminator. 
2.7 Slide observation under fluorescence microscope 
The slide is placed on the stage, fluorescent cells were viewed, and the field of interest was 
set under 10X objective lens. Once the cells are clearly visible, the objective lens was 
changed to 50X for higher resolution and better image under oil immersion. The turret must 
be set to 20 for better image. The wavelength must be changed based on the type of filter 
being used (DAPI=1, GFP=2 and Texas Red=3). 
 
2.8 Selecting pictures using Infinity Capture  
The selection of the best field view of fluorescent cells will transfer the picture from the 
eyepiece to the camera. The camera settings must be optimized along with the exposure 
time suitable for the cell sample and must be kept constant throughout all treatments. The 
picture will be saved using the option called “Still Image” in the Infinity Capture program. 
 
2.9 Measuring corrected total cell fluorescence (CTCF)  
Fiji (ImageJ) software was used for measuring fluorescence. Individual distinct cells or 
stacked cells in groups post immunofluorescence were selected using freehand selection 
tool (Figure 5a). The area mean gray value and integrated density were selected in “Set 
measurements” under the “Analyze” menu in ImageJ. 
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The values were displayed once we select “Measure”. The background noise has been 
negated by selecting four areas on an average around each cell of interest in the field of 
view and measuring the background fluorescence for accumulating accurate intensities 
(Figure 5b). 
Corrected Total Cell Fluorescence (CTCF) was calculated after recording all the values 
from our total field of view using the following formula (Table 3)- 
 
CTCF = Integrated density – (Area of selected cell x Mean fluorescence of 
background readings) 
 
A graph is plotted and compared with different treatment groups. 
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Figure 5: (a) Measuring fluorescence using ImageJ. Individual cells (green) were 
selected using the freehand selection tool (yellow) and analyzed. Several parameters like 
area, mean and integrated density were measured. Stacked cells were selected all at once 
and the parameters measured. 
 
 
 
 
(a) 
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(b) Measuring background noise by selecting four areas around each cell. Four areas 
(yellow) around each cell were selected along with the parameters (area, mean and 
integrated density). In case of stacked cells, based on the number of individual cells present 
in the stack, the corresponding background areas were selected. 
 
 
 
 
 
(b) 
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2.10 Statistical Significance 
The statistical significance was calculated using One-Way ANOVA Sigma Plot 13.0. All 
experiments were performed in triplicates. 
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RESULTS 
 
M2c macrophages and IL-13 polarized M2a macrophages shift towards an increase 
in the expression of MERTK receptor in comparison to IL-4 treated M2a 
macrophages in flow cytometry 
Polarization of RAW 264.7 M0 macrophages after 24 hours with IL-10 and IL-13 followed 
by treatment with FITC anti-mouse MERTK (Mer) antibody (BioLegend) and FITC Rat 
IgG2a, k Isotype Control Antibody (BioLegend) showed an increasing trend in the 
expression of MERTK receptor in polarized M2c macrophages (Figure 7) when compared 
to polarized IL-4 treated M2a macrophage (Figure 6). The increase was statistically non-
significant. 
Overnight incubation of both polarized M2c macrophage and polarized M2a (treated with 
IL-13) macrophage expressed similar increase in the expression of MERTK receptors post 
treatment with FITC anti-mouse MERTK (Mer) antibody (BioLegend) and FITC Rat 
IgG2a, k Isotype Control Antibody (BioLegend) (Figure 6). 
 
IL-13 polarized M2a macrophages shift towards an increase of MERTK receptor 
expression in comparison to IL-4 polarized M2a macrophages in flow cytometry 
displaying the dynamic nature of macrophages 
Following 24-hour treatment of M0 macrophages with IL-13 and IL-4 and addition of FITC 
anti-mouse MERTK (Mer) antibody (BioLegend) and FITC Rat IgG2a, k Isotype Control 
Antibody (BioLegend), IL-13 polarized M2a macrophages showed an increasing trend in 
the expression of MERTK receptor (Figure 8 and Figure 9) than IL-4 polarized M2a 
macrophages . The increase was statistically non-significant. 
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Immunofluorescence green fluorescent protein (GFP) staining of M2c macrophages 
with SOCS3 significantly enhances the expression of MERTK receptor  
SOCS3 treated IL-10 polarized M2c macrophages significantly enhanced the expression 
of MERTK receptor when compared to SOCS3 treated M0 macrophages and IL-10 
polarized M2c macrophages (Figure 10, Supplemental Figure 1). The enhancement in the 
MERTK expression increases the phagocytic nature of SOCS3 treated M2c macrophages. 
There was a non-significant increase in the expression of MERTK receptor in SOCS3 
treated M2c macrophages when compared to M2c macrophages. 
 
SOCS3 treated M2c macrophages enhances the expression of MERTK receptor when 
compared to SOCS1 and SOCS3 treated M0 macrophages using immunofluorescence 
green fluorescent protein (GFP) staining 
Immunofluorescence staining after 24-hour polarization treatment of M0 macrophages 
with SOCS3+IL-10, SOCS1 and SOCS3 treated M0 macrophages, enhanced an increase 
in MERTK receptor expression in SOCS3 treated M2c macrophages (Figure 11). SOCS1 
negatively regulates the phagocytic nature of macrophages by decreasing the expression of 
MERTK receptor (Figure 11). 
 
GFP-Immunofluorescence stained M2c macrophages increases the expression of 
MERTK receptor when compared to SOCS1 and SOCS3 treated M0 macrophages  
The phagocytic ability of M2c macrophages are higher than SOCS1 and SOCS3 treated 
M0 macrophages due to the higher expression of MERTK receptor in IL-10 treated M2c 
macrophages (Figure 12). 
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IL-13 polarized M2a macrophage significantly increased the expression of MERTK 
receptor when compared to IFN-g polarized M1 phenotype and IL-4 polarized M2a 
macrophages using immunofluorescence staining 
Previous studies have observed an increase in Axl receptor with IL-13, which is structurally 
and functionally similar to MERTK receptor and belongs to the same family of TAM 
receptors. The current immunofluorescence study also displays a significant increase in the 
expression of MERTK receptor with IL-13 polarized M2a macrophages when compared 
to IFN-g treated M1 macrophages and IL-4 treated M2a macrophages (Figure 13, 
Supplemental Figure 3). 
 
SOCS3 negatively regulates the expression of IL-13 polarized M2a macrophages but 
significantly enhances the expression of IL-10 polarized M2c macrophages 
Immunofluorescence staining of 24-hour polarized SOCS3 treated IL-10 M2c 
macrophages significantly enhanced the expression of MERTK receptor whereas SOCS3 
treated IL-13 decreased the expression confirming the fact that SOCS3 only enhances the 
phagocytic capacity of IL-10 polarized M2c macrophages by increasing the expression of 
the phagocytic receptor MERTK (Figure 14, Supplemental Figure 2). SOCS1 treated IL-
10 polarized M2c macrophages also reduced MERTK expression acting as a negative 
regulator (Figure 14, Supplemental Figure 2). 
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FIGURES 
 
 
 
Figure 6: Expression of MERTK receptor between IL-10 polarized M2c 
macrophages, IL-13 polarized M2a macrophages and IL-4 polarized M2a 
macrophages at 24 hours using flow cytometry. The black bar represents IL-10 polarized 
M2c macrophages, IL-13 polarized M2a macrophages and IL-4 polarized M2a 
macrophages with FITC anti-mouse MERTK (Mer) primary antibody (BioLegend) and 
grey bars depicts treatment with FITC Rat IgG2a, k Isotype Control Antibody 
(BioLegend). IL-10 polarized M2c macrophages show an increasing trend in the 
expression of MERTK receptor. However, both IL-10 polarized M2c macrophages and IL-
13 polarized M2a macrophages show similar expression of MERTK receptor.  
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Figure 7: Flow histogram displaying a positive shift in the expression of MERTK 
receptor between IL-10 treated M2c macrophage (left) and untreated M0 
macrophage as control (right). (a) IL-10 treated M2c macrophages (left) and (b) 
untreated M0 macrophages (right) with FITC anti-mouse MERTK (Mer) primary antibody 
(BioLegend) is shown in black whereas the same set of cells with FITC Rat IgG2a, k 
Isotype Control Antibody (BioLegend) were shown in red.  
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Figure 8: Flow histogram displaying a positive shift in the expression of MERTK 
receptor between IL-13 treated M2a macrophage (left) and untreated M0 
macrophage as control (right). (a) IL-13 treated M2a macrophages (left) and (b) 
untreated M0 macrophages (right) with FITC anti-mouse MERTK (Mer) primary antibody 
(BioLegend) is shown in black whereas the same set of cells with FITC Rat IgG2a, k 
Isotype Control Antibody (BioLegend) were shown in red.  
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Figure 9: Dynamic nature of M2 macrophages exhibited during expression of 
MERTK receptor between IL-4 polarized M2a macrophages and IL-13 polarized 
M2a macrophages at 24 hours using flow cytometry. The black bar represents IL-4 
polarized M2a macrophages and IL-13 polarized M2a macrophages with FITC anti-mouse 
MERTK (Mer) primary antibody (BioLegend) and grey bars depicts treatment with FITC 
Rat IgG2a, k Isotype Control Antibody (BioLegend). IL-13 polarized M2a macrophages 
exhibit an increasing trend in MERTK expression when compared to IL-4 polarized M2a 
macrophages.  
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Table 3: Corrected Total Cell Fluorescence (CTCF) values for different macrophage 
polarized treatments using immunofluorescence staining. The CTCF values of the 
polarized macrophages were shown with respect to their binding with FITC anti-mouse 
MERTK (Mer) primary antibody (BioLegend). 
 
 
 
Macrophage treatments Total number of cells 
(n) 
Corrected Total Cell 
Fluorescence (CTCF) 
SOCS3+IL-10 polarized 
M2c 
40 106796.826 
 
IL-10 polarized M2c 43 73114.6853 
 
SOCS3 treated M0 40 65930.5357 
 
SOCS3+IL-13 polarized 
M2a 
 
51 38023.3569 
SOCS1 treated M0 37 30440.079 
 
IL-13 polarized M2a 60 166100.899 
 
IL-4 polarized M2a 97 71250.1304 
 
SOCS1+IL-10 polarized 
M2c 
65 45655.3833 
 
IFN-g polarized M1 68 59611.1139 
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Figure 10: Immunofluorescence staining using green fluorescence protein (GFP) 
filter for expressing MERTK receptor on SOCS3 treated polarized IL-10 M2c 
macrophage, SOCS3 treated M0 macrophage and IL-10 polarized M2c macrophage 
after 24 hours. The black bar represents SOCS3+IL-10, SOCS3 and IL-10 polarized 
macrophages treated with FITC anti-mouse MERTK (Mer) primary antibody (BioLegend) 
and grey bars depicts treatment with FITC Rat IgG2a, k Isotype Control Antibody 
(BioLegend). The stars on top of the bar graph shows significant increase in the expression 
of MERTK receptor. (All images above were captured at 500X oil magnification in 
fluorescent microscope, scale bar = 100 µm). (P<0.05 *) (n=total number of cells counted 
for fluorescence). 
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Figure 11: Immunofluorescence staining using green fluorescence protein (GFP) 
filter for expressing MERTK receptor on SOCS3 treated IL-10 polarized M2c 
macrophage, SOCS1 treated M0 macrophage and SOCS3 treated M0 macrophage 
after 24 hours. The black bar represents SOCS3+IL-10 polarized M2c, SOCS3 and 
SOCS1 treated M0 macrophages with FITC anti-mouse MERTK (Mer) primary antibody 
(BioLegend) and grey bars depicts treatment with FITC Rat IgG2a, k Isotype Control 
Antibody (BioLegend). The stars on top of the bar graph shows significant increase in the 
expression of MERTK receptor. (All images above were captured at 500X oil 
magnification in fluorescent microscope, scale bar = 100 µm). (P<0.05 *) (n=total number 
of cells counted for fluorescence). 
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Figure 12: Immunofluorescence staining using green fluorescence protein (GFP) 
filter for expressing MERTK receptor on IL-10 polarized M2c macrophage, SOCS1 
treated M0 macrophage and SOCS3 treated M0 macrophage after 24 hours. The black 
bar represents IL-10 polarized M2c, SOCS3 and SOCS1 treated M0 macrophages with 
FITC anti-mouse MERTK (Mer) primary antibody (BioLegend) and grey bars depicts 
treatment with FITC Rat IgG2a, k Isotype Control Antibody (BioLegend). The stars on top 
of the bar graph shows significant increase in the expression of MERTK receptor. (All 
images above were captured at 500X oil magnification in fluorescent microscope, scale bar 
= 100 µm). (P<0.05 *) (n=total number of cells counted for fluorescence). 
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Figure 13: Immunofluorescence staining using green fluorescence protein (GFP) 
filter for expressing MERTK receptor on IL-13 polarized M2a macrophage, IL-4 
polarized M2a macrophage and IFN-g polarized M1 macrophage after 24 hours. The 
black bar represents IL-13 polarized M2a macrophage, IL-4 polarized M2a macrophage 
and IFN-g polarized M1 macrophage with FITC anti-mouse MERTK (Mer) primary 
antibody (BioLegend) and grey bars depicts treatment with FITC Rat IgG2a, k Isotype 
Control Antibody (BioLegend). The stars on top of the bar graph shows significant increase 
in the expression of MERTK receptor. (All images above were captured at 500X oil 
magnification in fluorescent microscope, scale bar = 100 µm). (P<0.05 *) (n=total number 
of cells counted for fluorescence). 
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Figure 14: Immunofluorescence staining using green fluorescence protein (GFP) 
filter for expressing MERTK receptor on SOCS3 treated IL-10 polarized M2c 
macrophage, SOCS3 treated IL-13 polarized M2a phenotype and SOCS1 treated IL-
10 polarized M2c macrophage after 24 hours. The black bar represents SOCS3+IL-10 
polarized M2c macrophage, SOCS3+IL-13 polarized M2a macrophage and SOCS1+IL-10 
polarized M2c macrophage with FITC anti-mouse MERTK (Mer) primary antibody 
(BioLegend) and grey bars depicts treatment with FITC Rat IgG2a, k Isotype Control 
Antibody (BioLegend). The stars on top of the bar graph shows significant increase in the 
expression of MERTK receptor. (All images above were captured at 500X oil 
magnification in fluorescent microscope, scale bar = 100 µm). (P<0.05 *) (n=total number 
of cells counted for fluorescence). 
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DISCUSSION 
 
The trans-membrane receptor tyrosine kinase Mer (MERTK) present on the outer surface 
of macrophages is responsible for binding to the “eat me” signal, in this case 
phosphatidylserine (PtdSer) which are released by the apoptotic cell followed by 
engulfment of the cell. The current study focuses on the expression of the MERTK receptor 
on IL-10 treated M2c RAW 264.7 macrophages, IL-13 and IL-4 polarized M2a 
macrophages. IL-10 polarized M2c macrophages shows an increasing trend towards 
MERTK expression. The results also demonstrate an enhancement in the expression of the 
receptor by addition of KIR-SOCS3 to M2c macrophages when compared with 
SOCS3+IL-13 M2a macrophages (Figure 15). There is no increase observed in the 
MERTK receptor expression on SOCS3 and SOCS1 treated M0 macrophages which 
suggest that SOCS3 protein acts as a negative regulator of the MERTK receptor unless in 
combination with IL-10 polarized M2c phenotype. SOCS1 on the other hand acts as a 
negative regulator of MERTK receptor expression when treated with M0 macrophage and 
with IL-10 polarized M2c phenotype. 
Reports based on the current study showcase the dynamic, diverse, and plastic nature of 
macrophages as they readily switch from one phenotype to another when there are changes 
within the cytokine environment. The increase in the expression of MERTK receptor on 
IL-13 polarized M2a macrophages but not when compared to IL-4 polarized M2a 
macrophage exhibit the fact that two distinct cytokines which are responsible for polarizing 
RAW 264.7 macrophage into M2a phenotype have contrasting effects on the expression of 
MERTK receptor exhibit the flexible nature of macrophages. The increase of MERTK 
receptor expression on IL-13 polarized M2a macrophage in the current study aligns with 
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reports involving murine bone marrow derived macrophages (BMDMs) showing an 
increase in the expression of Axl receptor which belongs to the same family as MERTK, 
in IL-13 and IL-4 polarized M2a phenotype when compared to LPS and IFN-g polarized 
M1 macrophage (Myers et al., 2019). The MERTK-mRNA transcript levels also increases 
in IL-13 polarized M2a subtype in comparison to M1 phenotype (Myers et al., 2019). 
In cancer immunotherapy, not much progress has been made with M2 macrophage 
polarization. M2 macrophages polarized by IL-10 helps in tumor progression as there is a 
tendency to polarize macrophages into the anti-inflammatory phenotype in a tumor 
environment (Weagel et al., 2015). The current study with SOCS3 enhancing the 
expression of the phagocytic receptor MERTK on IL-10 polarized M2c macrophage might 
act as the perfect combination of factors required for SOCS3+ MERTK+ M2c macrophages 
to phagocytose cancer cells and exhibit anti-cancer properties in vivo. 
The lack of a significant increase in MERTK receptor expression statistically in flow 
cytometry is because of the asynchronous culture used during the study. The cell 
confluency on separate treatments had slight variations and the exact morphology and 
nature of the respective macrophage phenotype in culture based on their treatments were 
not finite. A small portion of the MERTK receptor called the tyrosine kinase domain (TKD) 
was present in the cytoplasmic region of the macrophage, hence the antibody in use could 
only detect the exposed region of the receptor. 
The current study enhancing the expression of phagocytic receptor MERTK on 
SOCS3+IL-10 M2c phenotype supports the data of Capan (2017) and Madhkhali (2019) 
on the positive impact of SOCS3 on IL-10 polarized M2c macrophages, increasing the 
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phagocytosis of tumor cells following blockage of CRT “eat me” signal (Capan, 2017) and 
upregulating the phagocytic capacity of macrophage for N2a cells (Madhkhali, 2019). 
 
 
 
Figure 15: Expression of MERTK receptor is enhanced by SOCS3 addition in IL-10 
polarized M2c macrophage, but not when added to IL-13 polarized M2a macrophage. 
Hence, SOCS3 negatively regulates MERTK receptor expression in IL-13 polarized M2a 
macrophage, although IL-13 increases the receptor expression when treated with M0 
macrophages. 
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FUTURE RESEARCH 
 
Previous studies have suggested that macrophage receptor expression and cytokine 
secretion are affected in an apoptotic environment. Expression of the phagocytic receptor 
MERTK on macrophages enhances uptake (phagocytosis) of nearby apoptotic cells 
releasing “eat-me” signals at their cell surfaces. Briefly, these “eat-me” signals increase 
the function of the MERTK ligands Gas6 and ProS on the macrophage to bridge with 
PtdSer present on the apoptotic cell, leading to MERTK-receptor mediated phagocytosis. 
Based on the results of this present study, in a future study, SOCS3 treated IL-10-polarized 
MERTK-positive M2c macrophages should exhibit a higher phagocytic rate of tumor cells 
such as N2a neuroblastoma cells, when compared to macrophages treated with IL-10 or 
IL-4 or IL-13 alone. The higher phagocytic rate of SOCS3+IL-10 polarized MERTK-
positive M2c macrophages would help in cancer diagnostics, where the combination of 
SOCS3+IL-10 might lead to engulfment of cancerous cells, which was not possible with 
IL-10 treatment alone. 
Although IL-10 polarized M2c macrophages shows a non-significant increase in MERTK 
expression by flow cytometry, IL-10 requires other factors like M-CSF and PPAR-g 
antagonists to enhance the MERTK expression than IL-10 alone. IL-10 along with M-CSF 
or PPAR-g would not only increase MERTK expression but might also increase the 
phagocytic rate around apoptotic cells. It would be interesting to observe the impact of 
SOCS3 when treated with a combination of IL-10+MCSF or IL-10+PPARg in an apoptotic 
environment.  
 
 
 
40 
Another factor to consider is that the TKD portion of the MERTK receptor is embedded in 
the cytoplasm and not exposed on the macrophage cell surface and hence is not readily 
identified by flow cytometry.  In the present study, immunofluorescent cytochemistry was 
able to differentiate the increase in expression of MERTK following cytokine treatments 
of IL-10, IL-13 and by SOCS3+IL-10 but not by SOCS3+IL-13.  Since IL-13 induces 
expression of the Axl receptor similar in structure to MERTK, future studies should be 
directed to determining if Axl expression is not enhanced by SOCS3 treatment of the M2a 
phenotype whereas MERTK expression is enhanced by S0CS 3 treatment of M2 phenotype 
macrophages as shown in the present study. 
M2a macrophages polarized with IL-13 might also exhibit have a phagocytic increase of 
N2a cells and this increase could be reversed by treatment of these IL-13 polarized 
macrophages with SOCS3 because SOCS3 did not enhance expression of MERTK on IL-
13-treated M2a macrophages while it did on IL-10-treated M2c macrophages.  
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SUPPLEMENTAL FIGURES 
 
 
 
 
Supplemental Figure 1. Immunofluorescence staining using green fluorescence 
protein (GFP) filter for comparing the expression of MERTK receptor on SOCS3 
treated IL-10 polarized M2c macrophage (a), SOCS3 treated M0 macrophage (b), 
and IL-10 polarized M2c macrophage (c) after 24 hours. SOCS3 treated IL-10 polarized 
SOCS 3 + IL-10 M2c + FITC anti-MerTK Ab
CTCF: 320654.98 CTCF: 208509.77 CTCF: 185370.56
+++ ++ +
a
SOCS 3 M0  + FITC anti-MerTK Ab
CTCF: 342102.158 CTCF: 257937.88 CTCF: 71293.746
+++ ++ +
b
IL-10 M2c + FITC anti-MerTK
CTCF: 273001.57 CTCF: 197063.69 CTCF: 191519.48
+++ ++ +
c
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M2c macrophages enhances the expression of MERTK receptor. SOCS3 alone negatively 
regulates MERTK receptor expression on M0 macrophages. (All images above were 
captured at 500X oil magnification in fluorescent microscope, scale bar = 100 µm). 
(+++, ++, + = decreasing order of fluorescence). 
 
 
 
 
 
SOCS 3 + IL-10 M2c + FITC anti-MerTK Ab
CTCF: 320654.98 CTCF: 208509.77 CTCF: 185370.56
+++ ++ +
a
SOCS 3 + IL-13 M2a + FITC anti-MerTK Ab
CTCF: 460082.011 CTCF: 44431.42 CTCF: 24038.439
+++ ++ +
b
SOCS 1 + IL-10 M2c + FITC anti-MerTK Ab
+++ ++ +
CTCF: 76420.8333 CTCF: 64225.9398 CTCF: 20730.612
c
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Supplemental Figure 2. Immunofluorescence staining using green fluorescence 
protein (GFP) filter for comparing the expression of MERTK receptor on SOCS3 
treated IL-10 polarized M2c macrophage (a), SOCS3 treated IL-13 polarized M2a 
macrophage (b), and SOCS1 treated IL-10 polarized M2c macrophage (c) after 24 
hours. SOCS3 only enhances the MERTK receptor expression when combined with IL-10 
polarized M2c phenotype. SOCS3 reduces the receptor expression when combined with 
IL-13. SOCS1 negatively regulated MERTK receptor expression on IL-10 polarized M2c 
phenotype. (All images above were captured at 500X oil magnification in fluorescent 
microscope, scale bar = 100 µm). (+++, ++, + = decreasing order of fluorescence). 
 
 
 
 
 
IL-13 M2a + FITC anti-MerTK
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aIL-4 M2a + FITC anti-MerTK
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b
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Supplemental Figure 3. The dynamic nature of M2 macrophages were exhibited 
during immunofluorescence staining using green fluorescence protein (GFP) filter for 
comparing the expression of MERTK receptor on IL-13 polarized M2a macrophage 
(a) and IL-4 polarized M2a macrophage (b) after 24 hours. Both IL-13 and IL-4 
polarizes M2a macrophage, but only IL-13 increases MERTK receptor expression and IL-
4 has no significant increase. This expresses the flexible nature of M2c macrophage 
phenotype. (All images above were captured at 500X oil magnification in fluorescent 
microscope, scale bar = 100 µm). (+++, ++, + = decreasing order of fluorescence). 
 
 
 
